Our Projects

Better access to medicine

For most people in the world there is insufficient provision of medical care. Also the access to medicine does not correspond to their needs. Whereas four persons out of five of the world population are living in developing countries, their share in the pharmaceutical market is just a fifth of it. This disproportion becomes very evident in two examples: AIDS drugs and neglected diseases. more ...

Stop useless drugs

German pharmaceutical companies are among the biggest suppliers of drugs in the Third World. For the fourth time BUKO Pharma-Kampagne has asked experts to evaluate the supply of drugs of German manufacturers to the South. The result of the study: Almost 1000 (39%) out of more than 2.500 tested drugs have to be regarded as irrational according to pharmacological and clinical criteria. more...

Drug marketing

Pharmaceutical Industry: Its influence can be found on all levels – from trying to raise the drug turnover made by research companies, through to medical practitioners and end consumers. BUKO Pharma-Kampagne makes this influence public. It wants health policy to have one high principle: the well-being of the patients. more ...


No life without pills? The medicalization of everyday life

Medicines have become a new society drug. It is pretended that there is a remedy for and against everything. more...

Who benefits from Public Private Partnerships?

For public health campaigns less and less money is available: childhood vaccinating campaigns, as well as campaigns against malaria, AIDS, tuberculosis and sleeping sickness all come to a temporary halt. The concept of the public private partnerships (PPP) is meant to end this dreadful state of affairs. more...

Poverty makes sick

Millions of people in Africa, Asia and Latin America are suffering from serious diseases. High hopes are pinned on the expensive drugs from the industrialised countries. Often these hopes are too high. more...

Medicine in Europe

Important principles of the drug policy are currently regulated on a European level. This is of double significance. Firstly, the population in Europe is directly affected. But European policy regarding drug regulation has also indirect effects on the population in poor regions of the Third World. more...